The acquisition of Nimble Therapeutics by AbbVie is likely to have a positive short-term impact on AbbVie's stock price. The addition of Nimble's lead asset and other novel oral peptide assets will strengthen AbbVie's immunology pipeline, addressing significant unmet needs in autoimmune diseases. Furthermore, access to Nimble's proprietary peptide synthesis platform could enhance AbbVie's capabilities in discovering and optimizing oral peptide therapeutics, potentially leading to future growth and innovation.